News | April 03, 2023
EIP Pharma and Diffusion Pharmaceuticals inks agreement to create CNS-focused company
EIP Pharma to initiate in 2Q 2023 a Phase 2b clinical study, funded in part by a $21 million grant from the National Institute of Aging